1
|
Simula L, Fumagalli M, Vimeux L, Rajnpreht I, Icard P, Birsen G, An D, Pendino F, Rouault A, Bercovici N, Damotte D, Lupo-Mansuet A, Alifano M, Alves-Guerra MC, Donnadieu E. Mitochondrial metabolism sustains CD8 + T cell migration for an efficient infiltration into solid tumors. Nat Commun 2024; 15:2203. [PMID: 38467616 PMCID: PMC10928223 DOI: 10.1038/s41467-024-46377-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Accepted: 02/26/2024] [Indexed: 03/13/2024] Open
Abstract
The ability of CD8+ T cells to infiltrate solid tumors and reach cancer cells is associated with improved patient survival and responses to immunotherapy. Thus, identifying the factors controlling T cell migration in tumors is critical, so that strategies to intervene on these targets can be developed. Although interstitial motility is a highly energy-demanding process, the metabolic requirements of CD8+ T cells migrating in a 3D environment remain unclear. Here, we demonstrate that the tricarboxylic acid (TCA) cycle is the main metabolic pathway sustaining human CD8+ T cell motility in 3D collagen gels and tumor slices while glycolysis plays a more minor role. Using pharmacological and genetic approaches, we report that CD8+ T cell migration depends on the mitochondrial oxidation of glucose and glutamine, but not fatty acids, and both ATP and ROS produced by mitochondria are required for T cells to migrate. Pharmacological interventions to increase mitochondrial activity improve CD8+ T cell intratumoral migration and CAR T cell recruitment into tumor islets leading to better control of tumor growth in human xenograft models. Our study highlights the rationale of targeting mitochondrial metabolism to enhance the migration and antitumor efficacy of CAR T cells in treating solid tumors.
Collapse
Affiliation(s)
- Luca Simula
- Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris-Cité, Equipe labellisée "Ligue contre le Cancer", Paris, 75014, France.
| | - Mattia Fumagalli
- Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris-Cité, Equipe labellisée "Ligue contre le Cancer", Paris, 75014, France
| | - Lene Vimeux
- Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris-Cité, Equipe labellisée "Ligue contre le Cancer", Paris, 75014, France
| | - Irena Rajnpreht
- Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris-Cité, Equipe labellisée "Ligue contre le Cancer", Paris, 75014, France
| | - Philippe Icard
- Université de Normandie, UNICAEN, Inserm U1086 Interdisciplinary Research Unit for Cancer Prevention and Treatment, Caen, France
- Thoracic Surgery Department, Cochin Hospital, APHP-Centre, Université Paris-Cité, Paris, France
| | - Gary Birsen
- Department of Pneumology, Thoracic Oncology Unit, Cochin Hospital, APHP-Centre, Université Paris-Cité, 75014, Paris, France
| | - Dongjie An
- Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris-Cité, Equipe labellisée "Ligue contre le Cancer", Paris, 75014, France
| | - Frédéric Pendino
- Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris-Cité, Equipe labellisée "Ligue contre le Cancer", Paris, 75014, France
| | - Adrien Rouault
- Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris-Cité, Equipe labellisée "Ligue contre le Cancer", Paris, 75014, France
| | - Nadège Bercovici
- Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris-Cité, Equipe labellisée "Ligue contre le Cancer", Paris, 75014, France
| | - Diane Damotte
- Department of Pathology, Cochin Hospital, APHP-Centre, Université Paris-Cité, 75014, Paris, France
| | - Audrey Lupo-Mansuet
- Department of Pathology, Cochin Hospital, APHP-Centre, Université Paris-Cité, 75014, Paris, France
| | - Marco Alifano
- Thoracic Surgery Department, Cochin Hospital, APHP-Centre, Université Paris-Cité, Paris, France
- Inserm U1138, Integrative Cancer Immunology Unit, 75006, Paris, France
| | | | - Emmanuel Donnadieu
- Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris-Cité, Equipe labellisée "Ligue contre le Cancer", Paris, 75014, France.
| |
Collapse
|
2
|
Baber A, Legendre P, Palmic P, Lupo-Mansuet A, Burroni B, Azoulay C, Szwebel TA, Costedoat-Chalumeau N, Leroy K, Blons H, Blay JY, Boudou-Rouquette P, Terrier B. EBV-Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Spleen: Report of an Aggressive Form With Molecular Characterization. Int J Surg Pathol 2024; 32:150-154. [PMID: 37157817 DOI: 10.1177/10668969231168345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
EBV-positive inflammatory follicular dendritic cell sarcoma (EBV+ inflammatory FDCS) is a rare neoplasm almost exclusively located in the spleen or liver. It is characterized by a proliferation of EBV-positive spindle-shaped cells bearing follicular dendritic cell markers, associated with an abundant lymphoplasmacytic infiltrate. EBV+ inflammatory FDCS is often asymptomatic or responsible for mild symptoms. It usually displays an indolent course and its prognosis is excellent after tumor removal, although relapsing and metastatic forms exist. Herein, we describe an aggressive form of splenic EBV+ inflammatory FDCS in a 79-year-old woman presenting with abdominal pain, deterioration of general health status, major inflammatory syndrome, and symptomatic hypercalcemia. A splenectomy was performed leading to a rapid improvement in her clinical condition and normalization of laboratory abnormalities. Unfortunately, her symptoms and laboratory abnormalities reappeared 4 months later. Computed tomography showed a mass in the splenectomy site and multiple liver and peritoneal nodules. Further analyses were performed on tumor tissue and showed positive phospho-ERK staining of tumoral cells indicating activation of MAPK pathway. Inactivating mutations were found on CDKN2A and NF1 genes. Subsequently, the patient's condition deteriorated rapidly. Since interleukin-6 levels were dramatically increased, tocilizumab was used but only had a transient effect on the patient's symptoms and inflammatory syndrome. Antitumor agent gemcitabine was initiated but her clinical condition continued to deteriorate and the patient died 2 weeks later. The management of aggressive forms of EBV+ inflammatory FDCS remains challenging. However, since these tumors seem to display genetic alterations, better characterization could lead to molecular targeted therapies.
Collapse
Affiliation(s)
- Alistair Baber
- Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, University of Paris, Paris, France
| | - Paul Legendre
- Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, University of Paris, Paris, France
| | - Patricia Palmic
- Department of Pathology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, University of Paris, Paris, France
| | - Audrey Lupo-Mansuet
- Department of Pathology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, University of Paris, Paris, France
| | - Barbara Burroni
- Department of Pathology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, University of Paris, Paris, France
| | - Célia Azoulay
- Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, University of Paris, Paris, France
| | - Tali-Anne Szwebel
- Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, University of Paris, Paris, France
| | - Nathalie Costedoat-Chalumeau
- Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, University of Paris, Paris, France
| | - Karen Leroy
- Department of Medical Biology, Genomic Medicine and Physiology, Assistance Publique-Hôpitaux de Paris, European Hospital Georges Pompidou, University of Paris, Paris, France
| | - Hélène Blons
- Department of Medical Biology, Genomic Medicine and Physiology, Assistance Publique-Hôpitaux de Paris, European Hospital Georges Pompidou, University of Paris, Paris, France
| | - Jean-Yves Blay
- Léon Bérard Oncology Center, Claude Bernard Lyon 1 University, Lyon, France
| | - Pascaline Boudou-Rouquette
- Department of Oncology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, University of Paris, Paris, France
| | - Benjamin Terrier
- Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, University of Paris, Paris, France
| |
Collapse
|
3
|
Ashton E, Arrondeau J, Jouinot A, Boudou-Rouquette P, Hirsch L, Huillard O, Ulmann G, Lupo-Mansuet A, Damotte D, Wislez M, Alifano M, Alexandre J, Goldwasser F. Impact of sarcopenia indexes on survival and severe immune acute toxicity in metastatic non-small cell lung cancer patients treated with PD-1 immune checkpoint inhibitors. Clin Nutr 2023; 42:944-953. [PMID: 37099986 DOI: 10.1016/j.clnu.2023.03.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 03/14/2023] [Accepted: 03/29/2023] [Indexed: 04/28/2023]
Abstract
BACKGROUND & AIMS Sarcopenia has long been associated with higher toxicity induced by anti-cancer treatments and shorter survival in patients with solid tumors. The creatinine-to-cystatin ratio (CC ratio, serum creatinine/cystatin C × 100) and the sarcopenia index (SI, serum creatinine × cystatin C (CysC)-based glomerular filtration rate (eGFRCysC)) are have been reported to be correlated with skeletal muscle mass. The aim of this study is to assess primarily whether the CC ratio and the SI could predict mortality in metastatic non-small cell lung cancer (NSCLC) patients treated with PD-1 inhibitors, and secondarily their impact on severe immune-related adverse effects (irAEs). METHODS From the prospective CERTIM cohort, we analyzed retrospectively stage IV NSCLC patients, who received PD-1 inhibitors between June 2015 and November 2020 in Cochin Hospital (Paris, France). We assessed sarcopenia measuring skeletal muscle area (SMA) by computed tomography and handgrip strength (HGS) by a hand dynamometer. RESULTS In total, 200 patients were analyzed. The CC ratio and the IS were significantly correlated with SMA and HGS: rCC/SMA = 0.360, rSI/SMA = 0.407, rCC/HGS = 0.331, rSI/HGS = 0.370. In multivariate analysis of overall survival, a lower CC ratio (HR 1.73, P = 0.033) and a lower SI (HR 1.89, P = 0.019) were independent predictors of poor prognosis. In univariate analysis of severe irAEs, CC ratio (OR 1.01, P = 0.628) and SI (OR 0.99, P = 0.595) were not associated with a higher risk of severe irAEs. CONCLUSIONS In metastatic NSCLC patients treated with PD-1 inhibitors, a lower CC ratio and a lower SI are independent predictors of mortality. However, they are not associated with severe irAEs.
Collapse
Affiliation(s)
- Elisabeth Ashton
- Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France.
| | - Jennifer Arrondeau
- Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Cochin Hospital, Université Paris Cité, APHP.Centre, 75014 Paris, France.
| | - Anne Jouinot
- Université Paris Cité, Institut Cochin, INSERM U-1016, CNRS UMR-8104, 75014 Paris, France; Department of Endocrinology, Cochin Hospital, Université Paris Cité, APHP.Centre, 75014 Paris, France
| | - Pascaline Boudou-Rouquette
- Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Cochin Hospital, Université Paris Cité, APHP.Centre, 75014 Paris, France
| | - Laure Hirsch
- Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Cochin Hospital, Université Paris Cité, APHP.Centre, 75014 Paris, France
| | - Olivier Huillard
- Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Cochin Hospital, Université Paris Cité, APHP.Centre, 75014 Paris, France
| | - Guillaume Ulmann
- Department of Clinical Chemistry, Cochin Hospital, Université Paris Cité, APHP.Centre, 75014 Paris, France
| | - Audrey Lupo-Mansuet
- Department of Pathology, Cochin Hospital, Université Paris Cité, APHP.Centre, 75014 Paris, France
| | - Diane Damotte
- Department of Pathology, Cochin Hospital, Université Paris Cité, APHP.Centre, 75014 Paris, France
| | - Marie Wislez
- Department of Respiratory Medicine and Thoracic Oncology, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France
| | - Marco Alifano
- Department of Thoracic Surgery, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France
| | - Jérôme Alexandre
- Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Cochin Hospital, Université Paris Cité, APHP.Centre, 75014 Paris, France
| | - François Goldwasser
- Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Université Paris Cité, APHP.Centre, 75014 Paris, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Cochin Hospital, Université Paris Cité, APHP.Centre, 75014 Paris, France.
| |
Collapse
|
4
|
Chen J, Arrondeau J, Jouinot A, Rouquette PB, Fabre E, Giraud F, Chapron J, Huillard O, Lupo-Mansuet A, Damotte D, Alexandre J, Wislez M, Goldwasser F. 1048P Should I stay or should I go: Optimal duration for antiPD(L)1 therapy. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
5
|
Gervais C, Boudou-Rouquette P, Jouinot A, Chapron J, Arrondeau J, Alifano M, Giraud F, Huillard O, Alexandre J, Vazeille C, Durand JP, Leroy K, Revel MP, Bandt JPD, Cynober L, Damotte D, Lupo-Mansuet A, Goldwasser F. Abstract 1693: Prediction of the efficacy of nivolumab using resting energy expenditure in metastatic non-small cell lung cancer (mNSCLC) patients. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-1693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Immune evasion and deregulation of energy metabolism play a pivotal role in cancer progression. Immunosuppression in the tumor microenvironment can be based on the mutual metabolic requirements of immune and tumor cells. We evaluated the value of resting energy expenditure (REE) as a predictor of outcome, in mNSCLC patients under Nivolumab, an immune checkpoint inhibitor.
Methods: We studied the relation between REE, clinical and biological markers of cachexia and inflammation, and response to Nivolumab in 82 consecutive mNSCLC patients. Efficacy was assessed every 2 months according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria. REE was measured using indirect calorimetry, before the initiation of Nivolumab. According to their REE and with the use of Boothby's standard, patients were categorized as hypermetabolic, normometabolic and hypometabolic. Body mass index (BMI), performance status (PS), C-reactive protein (CRP), albumin, Neutrophil Lymphocyte R Ratio (NLR) and PD-L1 tumor expression were also recorded.
Results: Patients characteristics were: 62% males, median age of 65 years (range 37-78), 61% PS 0-1, median BMI of 24 kg.m-² (range 17-39), 78% nonsquamous NSCLC. The analysis of REE was available for 69 out of 82 consecutive pts: 37.7% were hypermetabolic, 47.8% were normometabolic, and 14.5% were hypometabolic. In univariate analysis, hypometabolism was a strong predictive marker of disease progression (Table 1), with positive and negative predictive values of 0.80 and 0.52 respectively. In multivariate analysis, independent parameters associated with disease progression were baseline hypometabolism (vs normometabolism: OR 1.77 [1.31-2.39] p= 0.0004) and albumin (per 1pt increase: OR 0.96 [0.94-0.99] p= 0.005).
Conclusion: Rest energy expenditure assessed by calorimetry appears as a biomarker of nivolumab clinical activity independently of PD1/PDL1 status.
Table 1Disease control (best response) n (%)<85% calculated REE n=10 (14.5%) Hypometabolic85-115% calculated REE n=33 (47.8%) Normometabolic>115% calculated REE n=26 (37.7%) Hypermetabolicunivariate OR (Hypometabolic vs normometabolic)pProgression8 (80%)11 (33%)17 (65%)8 [1.4-44.2]0.0007Disease control rate2 (20%)22 (67%)9 (35%)
Citation Format: Claire Gervais, Pascaline Boudou-Rouquette, Anne Jouinot, Jeanne Chapron, Jennifer Arrondeau, Marco Alifano, Frédérique Giraud, Olivier Huillard, Jérôme Alexandre, Clara Vazeille, Jean-Philippe Durand, Karen Leroy, Marie-Pierre Revel, Jean-Pascal de Bandt, Luc Cynober, Diane Damotte, Audrey Lupo-Mansuet, François Goldwasser. Prediction of the efficacy of nivolumab using resting energy expenditure in metastatic non-small cell lung cancer (mNSCLC) patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1693.
Collapse
Affiliation(s)
- Claire Gervais
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | | | - Anne Jouinot
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | - Jeanne Chapron
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | - Jennifer Arrondeau
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | - Marco Alifano
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | - Frédérique Giraud
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | - Olivier Huillard
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | - Jérôme Alexandre
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | - Clara Vazeille
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | | | - Karen Leroy
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | - Marie-Pierre Revel
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | | | - Luc Cynober
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | - Diane Damotte
- 1Cochin Hospital, CERTIM, AP-HP, Paris Descartes University, Paris, France
| | | | | |
Collapse
|